Our diligence and decision support work is grounded in scientific, commercial, and regulatory analysis.

We provide rigorous analytic and technical assessments that help investors, operators, and BD teams derisk key decisions. Our diligence frameworks integrate scientific depth with commercial clarity, enabling disciplined evaluation of programs, teams, and transactions.

Scientific & Commercial Due Diligence
End-to-end review of target assets, programs, or platforms—including mechanism rationale, preclinical/clinical evidence, competitive alternatives, and technical risks. We benchmark candidates against peer programs to define true differentiation and probability of success.

Deal Analytics & Investment Cases
Construction of integrated business cases that incorporate valuation, scenario models, and sensitivity analyses. We quantify upside, risk exposure, and required inflection milestones to strengthen negotiation positions and decision-making.

Epidemiology & Forecasting Models
Custom prevalence, incidence, and demand projections built from high-quality epidemiological sources and treatment-pattern logic. Models translate disease burden into realistic addressable-market estimates tailored to each mechanism and target population.

KOL Insight Generation
Design and execution of targeted primary research campaigns with clinicians, researchers, and payers. We synthesize insights to validate assumptions, pressure-test hypotheses, and uncover clinical or commercial dynamics not evident in secondary data.

Regulatory Pathway Assessment
High-level mapping of IND and Phase 1–3 requirements, timelines, and technical expectations. We evaluate CMC readiness, clinical feasibility, and global regulatory considerations to inform development planning and investor diligence.